Prospective Randomized Group Controlled Study of Clinical Efficacy and Safety of the CE marked Vivira App “In-Home Therapeutic Training Program”

Prospective Randomized Group Controlled Study of Clinical Efficacy and Safety of the CE marked Vivira App “In-Home Therapeutic Training Program” - Vivira20-22

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00022781

Enrollment

198

Registered

2020-11-02

Start date

2020-11-16

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Other indications: M99.02, M99.03, M99.04, M99.82, M99.83, M99.84, M99.92, M99.93, M99.94, M42.0, M42.9, M54.4 M42.1 M54.9 M53.2 M53.8 M53.9 M54.5 M54.6 M54.8

Interventions

Group 1: Personalized exercise therapy with the Vivira app. Execution of exercises and educations according to guidelines, which are digitally adapted to the individual performance of the patient. Gro

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adult patients with back/spinal pain; baseline pain score of 4 or more

Exclusion criteria

Exclusion criteria: Serious internal, neurological, vision, spine or bone disease

Design outcomes

Primary

Measure	Time frame
Pain reduction measured by VNRS after 2, 6 and 12 weeks	—

Secondary

Measure	Time frame
Function improvement of mobility	—

Countries

Germany

Contacts

Public ContactHans-Peter Zenner

Facharztpraxis

office@hpzenner.de+49707149645

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 11, 2026